Reutericyclin and related analogues kill stationary phase Clostridium difficile at achievable colonic concentrations

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 8, 2011, Pages 1773-1776

  Hurdle, Julian G ^a,b   Heathcott, Amy E ^a   Yang, Lei ^a   Yan, Bing ^a   Lee, Richard E ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

Author keywords

Anti C. difficile; Probiotic metabolite; Reutericyclins; Stationary phase

Indexed keywords

METRONIDAZOLE; PROBIOTIC AGENT; REUTERICYCLIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CLOSTRIDIUM DIFFICILE; COLON; DRUG EFFICACY; DRUG POTENCY; DRUG TRANSPORT; GASTROINTESTINAL TRACT; INTESTINE ABSORPTION;

ANTI-BACTERIAL AGENTS; CACO-2 CELLS; CLOSTRIDIUM DIFFICILE; COLON; HUMANS; MICROBIAL VIABILITY; TENUAZONIC ACID;

EID: 79960466763     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr201     Document Type: Article

References (10)

1. McFarland LV. Emerging therapies for Clostridium difficile infections. Expert Opin Emerg Drugs 2011; doi:10.1517/14728214.2011.571204.
2. Warny M, Pepin J, Fang A et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: 1079-84.
3. Hurdle JG, O'Neill AJ, Chopra I et al. Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat Rev Microbiol 2011; 9: 62-75.
4. Yendapally R, Hurdle JG, Carson EI et al. N-substituted 3-acetyltetramic acid derivatives as antibacterial agents. J Med Chem 2008; 51: 1487-91.
5. Hurdle JG, Yendapally R, Sun D et al. Evaluation of analogs of reutericyclin as prospective candidates for treatment of staphylococcal skin infections. Antimicrob Agents Chemother 2009; 53: 4028-31.
6. Zhai S, Yang L, Cui QC et al. Tumor cellular proteasome inhibition and growth suppression by 8-hydroxyquinoline and clioquinol requires their capabilities to bind copper and transport copper into cells. J Biol Inorg Chem 2010; 15: 259-69.
7. Bartlett JG. The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection. Clin Infect Dis 2008; 46: 1489-92.
8. Ganzle MG, Holtzel A, Walter J et al. Characterization of reutericyclin produced by Lactobacillus reuteri LTH2584. Appl Environ Microbiol 2000; 66: 4325-33.
9. Ochsner UA, Bell SJ, O'Leary AL et al. Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model. J Antimicrob Chemother 2009; 63: 964-71.
10. Goulding D, Thompson H, Emerson J et al. Distinctive profiles of infection and pathology in hamsters infected with Clostridium difficile strains 630 and B1. Infect Immun 2009; 77: 5478-85.